Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00034957 · ClinicalTrials.gov registry record · Phase 2

Study of the Efficacy of an Investigational Drug in Adult Patients With Non Small-Cell Lung Cancer (NSCLC)

A Phase 2 study of Carcinoma, Non-Small Cell Lung and Lung Neoplasms, sponsored by Pfizer.

Completed
Registry status
Phase 2
Development phase
12
Study locations

NCT00034957: Completed Phase 2 study of Carcinoma, Non-Small Cell Lung and Lung Neoplasms, sponsored by Pfizer.

NCT00034957 is a Phase 2 study of Carcinoma, Non-Small Cell Lung and Lung Neoplasms that has completed, run by Pfizer. The trial reports 12 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00034957, a Phase 2 study of Carcinoma, Non-Small Cell Lung and Lung Neoplasms, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 2
Development phase
12
Study locations

Study Summary

The primary goal of the study is to evaluate an investigational drug's effectiveness as a treatment for Non small-cell lung cancer (NSCLC)

Conditions Studied

Carcinoma, Non-Small Cell Lung Lung Neoplasms

Interventions

  • DRUG Investigational drug

Study Locations (12)

California

  • Research Center - Berkeley
  • Research Center - Greenbrae
  • Research Center - Los Angeles
  • Research Center - Rancho Mirage

Texas

  • Research Center - Arlington
  • Research Center - Dallas

Illinois

  • Research Center - Chicago

Kentucky

  • Research Center - Louisville

Massachusetts

  • Research Center - West Boylston

Michigan

  • Research Center - Ann Arbor

New Hampshire

  • Research Center - Lebanon

Tennessee

  • Research Center - Nashville

Trial Details

FieldValue
Est. Completion 2002-10
Phase Phase 2
Pfizer

1,845 total trials

What the finished NCT00034957 record still lists

NCT00034957 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.

The record links to 2 conditions, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 1 intervention - of which Investigational drug is the first listed.

NCT00034957 lists 12 locations in 8 states (California, Texas, Illinois).

Frequently Asked Questions

What is clinical trial NCT00034957 about?

NCT00034957 is a clinical study titled "Study of the Efficacy of an Investigational Drug in Adult Patients With Non Small-Cell Lung Cancer (NSCLC)". The primary goal of the study is to evaluate an investigational drug's effectiveness as a treatment for Non small-cell lung cancer (NSCLC)

What is the current status of trial NCT00034957?

This trial is currently completed. It is a Phase 2 study. Estimated completion is 2002-10.

What conditions does trial NCT00034957 study?

This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung, Lung Neoplasms.

What interventions are being tested in trial NCT00034957?

The interventions under investigation include: Investigational drug (DRUG).

Who is sponsoring clinical trial NCT00034957?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00034957 being conducted?

This trial has 12 study locations across California, Illinois, Kentucky, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Carcinoma, Non-Small Cell Lung

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Related registry views

Source: ClinicalTrials.gov NCT00034957, the US trial registry maintained by the National Library of Medicine. NCT00034957 (unsized enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.